Approved BTK Inhibitor Without Covalent Bond for CLL.

Published Date: 08 Dec 2023

In a patient population that had received extensive pretreatment, pirtobrutinib response rates were as high as 72%.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.

2.

Because of the Medicare mail-order drug rule, oncologists run the risk of self-referral violations.

3.

FDA approves Blenrep for relapsed or refractory multiple myeloma

4.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

5.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot